Loading market dashboard
Twist Bioscience Corporation
TWSTHealthcareNASDAQUS
Loading disclosure news
News and disclosures filtered by period, publisher, and event group.
Select a headline to open the full news page in the app.
This synthetic biology innovator, known for its DNA-based solutions, reported a notable insider sale amid a year of strong share gains.
Compare risk profiles, dividend strategies, and portfolio concentration as these two healthcare ETFs take different paths to long-term returns.
This synthetic biology firm, known for silicon-based DNA synthesis, reported a notable insider sale following strong one-year share gains.
Genomics and synthetic biology are reshaping healthcare, with growing demand for precision medicine spotlighting stocks like PACB, MYGN and TWST.
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Twist Bioscience Corporation (NASDAQ: TWST), a mid-cap growth and value biotech company, today announced that Emily M. Leproust, Ph.D., CEO and co-founder of Twist Bioscience and Adam Laponis, CFO of Twist Bioscience will present at the William Blair 46th Annual Growth Stock Conference on Tuesday, June 2, 2026 at 10:00 am Central Time in Chicago, Illinois. The presentation will be webcast live and can be accessed by visiting the “Investor Calendar”.
Twist Bioscience Corporation (TWST) Analyst/Investor Day Transcript
DÜSSELDORF, Germany--(BUSINESS WIRE)--LenioBio GmbH, a TechBio company commercializing its ALiCE® cell-free protein expression platform, today announced a collaborative agreement with Twist Bioscience Corporation. The collaboration will integrate our ALiCE® platform with Twist's DNA manufacturing and automation capabilities to accelerate the design–build–test cycle for protein expression services—delivering experimental results back to customers' and partners' AI models faster. “AI can design n.
Twist Bioscience (TWST) delivered strong Q2 results, driven by AI-enabled drug discovery. NGS growth was soft due to a demand air pocket caused by a large customer. Growth is expected to rebound as this company's commercial test volumes ramp. Twist's fundamentals are likely to continue improving in coming quarters. Growth investments will create modest near-term margin headwinds though.
Twist Bioscience Corporation (NASDAQ:TWST) on Monday reported a loss for its fiscal 2026 second quarter.
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--As required by the rules of the Nasdaq Stock Market, Twist Bioscience Corporation (NASDAQ: TWST) (“Twist” or the “Company”), a mid-cap growth and value biotech company, today announced that a total of 115,279 equity awards, consisting of 101,931 restricted stock units (“RSUs”) and up to 13,348 performance stock units (“PSUs”), will be granted to 53 recently hired individuals, in each case as an inducement material to their acceptance of employment w.
Twist Bioscience Corporation (TWST) Q2 2026 Earnings Call Transcript
Twist Bioscience Corporation (NASDAQ:TWST) shares are down on Monday as the company reported its fiscal 2026 second-quarter financial results.
Twist Bioscience (TWST) came out with a quarterly loss of $0.62 per share versus the Zacks Consensus Estimate of a loss of $0.54. This compares to a loss of $0.66 per share a year ago.
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Twist Bioscience Corporation (NASDAQ: TWST), a mid-cap growth and value biotech company, today expanded its clonal genes portfolio with the early access launch of Complex Genes. “As research in nucleic acid therapeutics and AI-guided protein design and therapeutics discovery accelerate, scientists need a reliable partner to consistently deliver genes rapidly at scale and with more complex sequences,” said Emily M. Leproust, Ph.D., CEO and co-founder.
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Twist Bioscience Corporation (NASDAQ: TWST), a mid-cap growth and value biotech company, today announced financial results and business highlights for the second quarter fiscal 2026 ended March 31, 2026. Visit the Events and Presentations page of the Investor Relations section under the “Company” tab at www.twistbioscience.com to view the detailed fiscal second quarter 2026 earnings report and the investor presentation, or click https://investors.tw.
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Twist Bioscience Corporation (NASDAQ: TWST), a mid-cap growth and value biotech company, today announced that it will issue its financial results for the fiscal 2026 second quarter ended March 31, 2026, before the opening of the market on May 4, 2026. The company plans to hold a conference call and live audio webcast for analysts and investors at 8:00 a.m. Eastern Time to discuss its financial results and provide an update on the company's business.
Twist Bioscience Corporation (NASDAQ: TWST - Get Free Report) CFO Adam Laponis sold 2,597 shares of the company's stock in a transaction that occurred on Thursday, April 9th. The shares were sold at an average price of $49.89, for a total value of $129,564.33. Following the completion of the transaction, the chief financial officer directly owned
Twist Bioscience Corporation (NASDAQ: TWST - Get Free Report) Director Melissa Starovasnik sold 1,000 shares of the firm's stock in a transaction dated Wednesday, April 1st. The stock was sold at an average price of $51.00, for a total transaction of $51,000.00. Following the completion of the transaction, the director directly owned 25,722 shares in the
SG Americas Securities LLC lifted its holdings in Twist Bioscience Corporation (NASDAQ: TWST) by 350.3% in the fourth quarter, according to the company in its most recent filing with the SEC. The fund owned 76,484 shares of the company's stock after acquiring an additional 59,500 shares during the quarter. SG Americas Securities LLC
Twist Bioscience Corporation (NASDAQ: TWST - Get Free Report) has earned a consensus recommendation of "Moderate Buy" from the nine brokerages that are presently covering the company, Marketbeat.com reports. Two research analysts have rated the stock with a sell rating and seven have given a buy rating to the company. The average 12 month target price
Twist Bioscience (NASDAQ: TWST - Get Free Report) and Zenas BioPharma (NASDAQ: ZBIO - Get Free Report) are both medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their institutional ownership, dividends, analyst recommendations, valuation, risk, earnings and profitability. Analyst Ratings This is a summary of current
Twist Bioscience Corporation (TWST) Presents at Barclays 28th Annual Global Healthcare Conference Transcript
Citigroup Inc. reduced its position in Twist Bioscience Corporation (NASDAQ: TWST) by 24.4% in the undefined quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 93,458 shares of the company's stock after selling 30,231 shares during the quarter. Citigroup Inc.
